Smith & Nephew PLC has settled a dispute with Synthes Inc. involving trochanteric nails for an undisclosed amount. Smith & Nephew (NYSE: SNN) has agreed to license its patents to Synthes and to ...

The study included 50 patients randomly assigned to receive either the Synthes trochanteric locking femoral nail (28 patients) or the expandable Fixion proximal femoral nail (22 patients).